PARTICIPATION IN CANCER AND LEUKEMIA GROUP B

该提案要求继续为机构提供资金。 参加纽约州立大学健康科学中心(北部 医学中心)，纽约锡拉丘兹，进行临床研究 癌症和白血病B组活动(CALGB)。CALGB IS 多机构合作研究小组致力于 系统地规划、启动、进行分析和报告 应用于恶性疾病患者治疗的研究。 CALGB的利益范围与我国的制度 参与的对象包括各种恶性疾病。这个 目前的CALGB提案涉及增加基于实验室的 评估也是如此。年我们机构的肿瘤学课程 与CALGB的合作是真正跨学科的，涉及 积极参与外科、放射治疗、临床病理、 精神病学、病理学、细胞遗传学和内科 (血液学和内科肿瘤学)北州医疗中心 积极参与CALGB计划的所有阶段。我们的 人员对集团的贡献很大，并在集团中占据突出地位 科学和行政领导，新的研究设计和 担任试点研究的主席、制定和执行 新化疗药物在I期和II期的测试 除了150多名患者的收益外，还进行试验 分组协议的条目/年。白血病参考文献 整个集团的实验室和委员会主席 位于我们机构的Lymphoma。作为结果， 这项提案和我们的机构提供的资金 承诺，患者的应计比率进入 可控的、可评估的、实验性的癌症治疗将是 维持在目前的较高水平。加宽和 我们机构临床研究计划的深化将 同样反映在我们科学研究的深度和广度上 以及对CALGB活动的行政参与。因为我们的 与CALGB的机构参与是 我们机构的跨学科癌症项目，附加 有益的效果将继续在教育中显现出来。 医科学生、内务人员、护理人员以及 纽约州中部的医生继续教育。在……里面 此外，与CALGB的合作将有助于将 最近在医疗保健和专业知识方面的最新进展 患者群体多样化。

This proposal requests continuation funding for institutional participation of the SUNY Health Science Center (Upstate Medical Center) Syracuse, New York, in the clinical research activities of Cancer and Leukemia Group B (CALGB). CALGB is a multi-institutional cooperative reserach group dedicated to the systematic planning, initiation, conduct analysis, and reporting of research as applied to therapy of patients with malignant disease. The scope of interest of CALGB and our institutional participation includes a wide variety of malignant disorders. The current CALGB proposal involves an increase in laboratory-based evaluations as well. The program in oncology at our institution in conjunction with CALGB is truly interdisciplinary, involving the active participation of Surgery, Radiotherapy, Clinical Pathology, Psychiatry, Pathology, Cytogenetics and Internal Medicine (Hematology and Medical Oncology). The Upstate Medical Center actively participates in all phases of the CALGB program. Our personnel contribute heavily to, and are prominent in, group scientific and administrative leadership, new study design and chairmanship, development and execution of pilot studies, the testing of new chemotherapeutic agents in phase I and phase II trials in addition to the accrual of greater than 150 patient entries/year to group protocols. The Leukemia Reference Laboratory for the entire group and the Committee Chairmanship in Lymphoma are located at our institution. As a result of the funding provided by this proposal and our institutional commitment, the accrual rate for patients entered into controlled, evaluable, experimental cancer therapy will be maintained at the current high level. The broadening and deepening of the clinical research program at our institution will similarly be reflected in the depth and breadth of our scientific and administrative involvement in CALGB activities. Since our institutional participation with CALGB is the core of the interdisciplinary cancer program at our institution, additional salutary effects will continue to be evident in the education of medical students, house officers, nursing staff as well as in the continuing education of physicians in mid-New York State. In addition, the collaboration with CALGB will help translate the most recent advances in medical care and expertise to a large and diversified patient population.